December 18, 2023 - CanSino Biologics Inc. (“CanSinoBIO”; SSE: 688185, HKEX: 06185), a leading Chinese biopharmaceutical company with a strong track record in the research, production, and commercialization of groundbreaking vaccines, and Saudi Pharmaceutical Industries and Medical Appliances Corpor...
CanSino Biologics Inc. (CanSinoBIO, stock 6185.HK) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide....
invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has successfully completed the acquisition of F-star Therapeutics, Inc. (“F-st...
“This is a great opportunity for us to work with CanSino Biologics Inc., one of the best vaccine companiesin China. It represents the result of the continuous evolution in biotechnology which has progressed through time in complementary sectors within the biopharmaceutical field.” -ENDS- AboutCa...
June 20th - 21st, 2012 China International Biopharmaceutical General Convention 2012- vaccines and antibody Focus June 29th - 30th, 2012 Beijing New Technology and Biomedical Applications Lecture Series October 19th - 21th, 2012 The 8th Annual Meeting of Chinese Society for Immunology 2011 Foreign Exh...
CanSino Biologics Inc. (CanSinoBIO) is a biopharmaceutical company that carries out research, development, manufacturing, and commercialization of vaccine products for human use. The company offers pipeline products such as the COVID-19 vaccine (adenovirus type 5 vector) for inhalation, group ACYW...
Pipeline Drugs Identify which of Sino Biopharmaceutical Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. 40+ Sales & Consensus Forecasts ...
Sino Biopharmaceutical Limited, or Sino Biopharm, a China-based Hang Seng Index company, and Boehringer Ingelheim, a global biopharmaceutical company, announced on Monday that they had entered into a strategic partnership focusing on bringing innovative cancer therapies to China, marking an important mil...
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, MPS and other diseases with significant unmet medical needs. The...
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained ...